Aligos Therapeutics, Inc. (ALGS) has 3 open-market insider trades by 3 insiders since 2020. The most active filer is Carole Nuechterlein, Director & 10% Owner.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Carole Nuechterlein | Dir10% Owner | — | 1 | $12.1M | 2023-10-25 |
| Vivo Capital Surplus Fund VIII, L.P. via Hongbo Lu | 10% Owner | — | 1 | $8.3M | 2020-10-20 |
| Thomas Woiwode | Dir | — | 1 | $3.0M | 2021-06-11 |
| Versant Venture Capital VI, L.P. | 10% Owner | — | 0 | — | 2020-10-20 |
| Novo Holdings A/S | 10% Owner | — | 0 | — | 2020-10-20 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Carole Nuechterlein | Director & 10% Owner | Buy | $12.1M | 2023-10-25 |
| Thomas Woiwode | Director | Buy | $3.0M | 2020-10-20 |
| Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Buy | $8.3M | 2020-10-20 |
Companies that share insiders with ALGS, and sector peers with recent insider buying. Related by who files, not by how the stocks move.